Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cyclophosphamide + Maveropepimut-S |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Maveropepimut-S | DPX-Survivac|MVP-S | DPX-Survivac (maveropepimut-S) is a liposome-encapsulated cancer vaccine that contains Survivin epitopes, which may induce an immune response against Survivin-expressing tumor cells (PMID: 26405584). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02323230 | Phase II | Cyclophosphamide + Maveropepimut-S | A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL | Terminated | CAN | 0 |